Skip to content

Price / sales at other companies

Intuitive Surgical logo
Intuitive SurgicalISRG
15.5×-4.9×
Theravance Biopharma logo
Theravance BiopharmaTBPH
7.6×+0.8×
LQD
Liquidia CorporationLQDA
11.5×-77.4×
United Therapeutics logo
United TherapeuticsUTHR
8.2×+3.6×
Viemed Healthcare, Inc. logo
Viemed Healthcare, Inc.VMD
1.2×0.0×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
4.5×-5.5×

Other financials

Income statement

See full
Revenue$20.6M-8.7%
Gross profit$16.0M-1.8%
Operating income-$13.0M+11.0%
Net income-$13.7M+5.5%
EPS (diluted)-$0.33+8.3%

Balance sheet

See full
Cash & equivalents$61.0M-2.4%
Total debt$56.3M-1.2%
Total equity$45.8M-41.1%
Total assets$120.0M-20.4%

Cash flow

See full
Operating cash flow-$10.1M+23.6%
CapEx$9.0K-97.0%
Free cash flow-$10.1M+25.3%

Valuation

See full
Market cap$54.91M-47.3%
Enterprise value$50.17M-43.5%

Profitability

See full
Gross margin75.5%+2.0pp
Operating margin-58.8%-5.8pp
Net margin-60.1%-4.4pp
FCF margin-33.2%-4.4pp

Returns & leverage

See full
Return on equity-86.2%+62.6pp
Debt / equity1.2×+0.5×
Current ratio4.9×-0.1×

Where this comes from

Calculated from Pulmonx Corporation’s reported figures.

Based on the most recent quarter.

The official record: Pulmonx Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulmonx Corporation's price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pulmonx Corporation's price / sales?
Pulmonx Corporation (LUNG) reported price / sales of 0.6× in Q1 2026.
How has Pulmonx Corporation's price / sales changed year-over-year?
Pulmonx Corporation's price / sales decreased by 79.9% year-over-year, from 3.1× to 0.6×.
What is the long-term trend for Pulmonx Corporation's price / sales?
Over 5 years (2020 to 2025), Pulmonx Corporation's price / sales has grown at a -57.7% compound annual growth rate (CAGR), from 74.6× to 1×.
What does price / sales mean?
Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.